PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30843693-6 2019 The Pearson"s correlation coefficient test elucidated that inorganics (EC), organics (OC, PAHs, and alkane), and metals (Cr, Mn, and Sb) were significantly correlated to the dysregulated oncoproteins (VEGF, IL6, MDM2, AKT1, STAT, and P53). Chromium 121-123 tumor protein p53 Homo sapiens 234-237 31388677-0 2019 p53 activation by Cr(VI): a transcriptionally limited response induced by ATR kinase in S-phase. Chromium 18-20 tumor protein p53 Homo sapiens 0-3 31388677-5 2019 Ascorbate-restored H460 and primary human cells treated with Cr(VI) contained higher levels of p53 and its Ser15 phosphorylation, which were induced by ATR kinase. Chromium 61-63 tumor protein p53 Homo sapiens 95-98 31388677-9 2019 A weak transcription activity of Cr(VI)-upregulated p53 was associated with its low lysine acetylation in the regulatory C-terminal domain, resulting from the inability of Cr(VI) to activate ATM in ascorbate-restored cells. Chromium 33-35 tumor protein p53 Homo sapiens 52-55 31388677-10 2019 Thus, p53 activation by ascorbate-metabolized Cr(VI) represents a limited genome-protective response that is defective in upregulation of DNA repair genes and proapoptotic transcripts for elimination of damaged cells. Chromium 46-48 tumor protein p53 Homo sapiens 6-9 26091798-13 2015 These results demonstrate that p53 is able to respond to exposure of arsenic or Cr(VI), suggesting that BEAS-2B cells are an appropriate in vitro model to investigate arsenic or Cr(VI) induced lung cancer. Chromium 80-82 tumor protein p53 Homo sapiens 31-34 28279036-9 2017 Patients with TP53 gene mutation were more likely to receive CR, 10 of 15 patients with TP53 mutations achieved CR. Chromium 61-63 tumor protein p53 Homo sapiens 14-18 28279036-9 2017 Patients with TP53 gene mutation were more likely to receive CR, 10 of 15 patients with TP53 mutations achieved CR. Chromium 112-114 tumor protein p53 Homo sapiens 14-18 28279036-9 2017 Patients with TP53 gene mutation were more likely to receive CR, 10 of 15 patients with TP53 mutations achieved CR. Chromium 112-114 tumor protein p53 Homo sapiens 88-92 27330773-10 2016 The p53 LIs were 24.5+-19.9, 25.7+-16.9 and 19.8+-13.8 in the CR, PR and SD/PD groups, respectively (P>0.05). Chromium 62-64 tumor protein p53 Homo sapiens 4-7 30501707-11 2018 The ORR in patients with TP53 mutation was high (P=0.04), moreover the patients with TP53 mutation more easily gained CR (P<0.001). Chromium 118-120 tumor protein p53 Homo sapiens 25-29 30501707-11 2018 The ORR in patients with TP53 mutation was high (P=0.04), moreover the patients with TP53 mutation more easily gained CR (P<0.001). Chromium 118-120 tumor protein p53 Homo sapiens 85-89 26091798-13 2015 These results demonstrate that p53 is able to respond to exposure of arsenic or Cr(VI), suggesting that BEAS-2B cells are an appropriate in vitro model to investigate arsenic or Cr(VI) induced lung cancer. Chromium 178-180 tumor protein p53 Homo sapiens 31-34 23515910-9 2013 The similar correlation between the wild-type form p53 and response to therapy were also detected in subgroup analyses (total MR, pathological MR, and total CR in chemoradiotherapy subgroup; total MR in chemotherapy subgroup; total MR and pathological CR in esophageal squamous cell carcinoma [ESCC]). Chromium 157-159 tumor protein p53 Homo sapiens 51-54 24530425-6 2014 Our results show that gestational exposure to CrVI resulted in (i) increased Cr concentration in the placenta, (ii) increased germ cell apoptosis by up-regulating p53/p27-Bax-caspase-3 proteins and by increasing p53-SOD-2 co-localization; (iii) accelerated germ cell cyst (GCC) breakdown; (iv) advanced primordial follicle assembly and primary follicle transition and (v) down regulation of p-AKT, p-ERK and XIAP. Chromium 46-48 tumor protein p53 Homo sapiens 163-166 24530425-6 2014 Our results show that gestational exposure to CrVI resulted in (i) increased Cr concentration in the placenta, (ii) increased germ cell apoptosis by up-regulating p53/p27-Bax-caspase-3 proteins and by increasing p53-SOD-2 co-localization; (iii) accelerated germ cell cyst (GCC) breakdown; (iv) advanced primordial follicle assembly and primary follicle transition and (v) down regulation of p-AKT, p-ERK and XIAP. Chromium 46-48 tumor protein p53 Homo sapiens 212-215 25156865-7 2015 TP53mut patients had lower response rates (22% compared with 76% CR in TP53 wild-type (wt) patients, P < 0.001) and reduced OS (2 and 16 months, respectively, P < 0.001). Chromium 65-67 tumor protein p53 Homo sapiens 0-4 25156865-7 2015 TP53mut patients had lower response rates (22% compared with 76% CR in TP53 wild-type (wt) patients, P < 0.001) and reduced OS (2 and 16 months, respectively, P < 0.001). Chromium 65-67 tumor protein p53 Homo sapiens 71-75 23942225-5 2013 CONCLUSION: Our research has disclosed the mechanism involved in Cr(VI)-induced cytotoxicity following the loss of p53 and caspase-3 functions and shed light on the importance of using antioxidants for primary and secondary prevention in Cr(VI) occupational exposure populations. Chromium 65-67 tumor protein p53 Homo sapiens 115-118 22886373-0 2012 Hexavalent chromium induces energy metabolism disturbance and p53-dependent cell cycle arrest via reactive oxygen species in L-02 hepatocytes. Chromium 11-19 tumor protein p53 Homo sapiens 62-65 22886373-9 2012 In summary, the present study provides experimental evidence that Cr(VI) leads to energy metabolism disturbance and p53-dependent cell cycle arrest via ROS in L-02 hepatocytes. Chromium 66-68 tumor protein p53 Homo sapiens 116-119 22791815-2 2012 However, both adenine (A) and guanine (G) mutations are found in the p53 gene in Cr exposure-related lung cancer. Chromium 81-83 tumor protein p53 Homo sapiens 69-72 22791815-5 2012 To understand the causes for these Cr-induced DNA damages, we mapped the distribution of BDA adducts and ODD in the p53 gene DNA fragments induced by Cr(III), Cr(VI) and Cr(V), the three major cellular Cr forms. Chromium 35-37 tumor protein p53 Homo sapiens 116-119 22791815-5 2012 To understand the causes for these Cr-induced DNA damages, we mapped the distribution of BDA adducts and ODD in the p53 gene DNA fragments induced by Cr(III), Cr(VI) and Cr(V), the three major cellular Cr forms. Chromium 150-152 tumor protein p53 Homo sapiens 116-119 22791815-5 2012 To understand the causes for these Cr-induced DNA damages, we mapped the distribution of BDA adducts and ODD in the p53 gene DNA fragments induced by Cr(III), Cr(VI) and Cr(V), the three major cellular Cr forms. Chromium 150-152 tumor protein p53 Homo sapiens 116-119 22791815-5 2012 To understand the causes for these Cr-induced DNA damages, we mapped the distribution of BDA adducts and ODD in the p53 gene DNA fragments induced by Cr(III), Cr(VI) and Cr(V), the three major cellular Cr forms. Chromium 150-152 tumor protein p53 Homo sapiens 116-119 22791815-5 2012 To understand the causes for these Cr-induced DNA damages, we mapped the distribution of BDA adducts and ODD in the p53 gene DNA fragments induced by Cr(III), Cr(VI) and Cr(V), the three major cellular Cr forms. Chromium 150-152 tumor protein p53 Homo sapiens 116-119 21881978-4 2012 The strong correlations of lower CR rate with advanced Binet stage, unmutated IGHV, cytogenetic abnormalities of del(17p13) or del(11q23), and p53 mutations were observed by univariable analyses. Chromium 33-35 tumor protein p53 Homo sapiens 143-146 19941740-4 2009 p53 mutation was detected in six out of 46 patients at initial diagnosis, three of them were out of 29 cases achieving complete remission (CR) and the other three cases were out of 17 of relapsed patients, which is significantly higher than CR group (P<0.05). Chromium 139-141 tumor protein p53 Homo sapiens 0-3 22521640-0 2012 WITHDRAWN: Hexavalent chromium induces premature senescence through reactive oxygen species-mediated p53 pathway in L-02 hepatocytes. Chromium 22-30 tumor protein p53 Homo sapiens 101-104 21194611-2 2011 Previous studies have demonstrated that arsenic and chromium complexes are able to activate p53, but there is a dearth of data investigating whether uranium complexes exhibit similar effects. Chromium 52-60 tumor protein p53 Homo sapiens 92-95 19941740-4 2009 p53 mutation was detected in six out of 46 patients at initial diagnosis, three of them were out of 29 cases achieving complete remission (CR) and the other three cases were out of 17 of relapsed patients, which is significantly higher than CR group (P<0.05). Chromium 241-243 tumor protein p53 Homo sapiens 0-3 17686239-9 2007 The CR rate of the p53 positive patients was 74%, higher than that of the p53 negative patients (44%, P = 0.065). Chromium 4-6 tumor protein p53 Homo sapiens 19-22 18024214-7 2008 2D gel analysis revealed p53 patterns in p21-/- cells were distinct from those in wild-type cells before and after chromium exposure. Chromium 115-123 tumor protein p53 Homo sapiens 25-28 18024214-2 2008 Chromium exposure resulted in a 500-1000 fold increase in apoptosis-induced cell death in p21-/- HCT116 cells compared to wild-type or p53-/- cells. Chromium 0-8 tumor protein p53 Homo sapiens 135-138 20306673-8 2008 In contrast to overexpression of MDM-2, the mutation of p53 was detected in 6 (13%) out of 46 ALL patients at the initial time of diagnosis, 3 of them (10.3%) were out of 29 cases of CR and the other 3 cases (17.6%) were out of 17 of relapsed group, which is significantly higher than CR group (P < 0.05). Chromium 183-185 tumor protein p53 Homo sapiens 56-59 20306673-8 2008 In contrast to overexpression of MDM-2, the mutation of p53 was detected in 6 (13%) out of 46 ALL patients at the initial time of diagnosis, 3 of them (10.3%) were out of 29 cases of CR and the other 3 cases (17.6%) were out of 17 of relapsed group, which is significantly higher than CR group (P < 0.05). Chromium 285-287 tumor protein p53 Homo sapiens 56-59 15140542-5 2004 The mean percentage of p53 positive cells was 28% in RT and 38% in B with 81% CR between B and RT and 19% FP on B. Chromium 78-80 tumor protein p53 Homo sapiens 23-26 16531837-5 2006 Western blotting showed increased p53 protein expression in MOLT-4 cells, but not in BEAS-2B cells, after exposure to 0.5 and 3 muM hexavalent chromium for 12 hours and 4 hours, respectively. Chromium 143-151 tumor protein p53 Homo sapiens 34-37 16887109-5 2006 Cr(VI) (50, 10 and 1 microM) was found to produce time- and dose-dependent cytotoxicity resulting in oxidative stress, suppression of antioxidant systems and activation of p53-dependent apoptosis which is reported for the first time in this model in relation to environmental Cr(VI). Chromium 0-2 tumor protein p53 Homo sapiens 172-175 16887109-5 2006 Cr(VI) (50, 10 and 1 microM) was found to produce time- and dose-dependent cytotoxicity resulting in oxidative stress, suppression of antioxidant systems and activation of p53-dependent apoptosis which is reported for the first time in this model in relation to environmental Cr(VI). Chromium 276-278 tumor protein p53 Homo sapiens 172-175 16251206-2 2006 Cr(VI) exposure-related lung cancer has a high mutation incidence in the p53 gene. Chromium 0-2 tumor protein p53 Homo sapiens 73-76 11407516-11 2001 The p53 mutation was noted in 16 patients: NR in 5 patients, PR in 9 patients, and CR in 2 patients (P = .638). Chromium 83-85 tumor protein p53 Homo sapiens 4-7 15163545-1 2004 It has been reported that the hexavalent chromium compound (Cr(VI)) can induce both p53-dependent and p53-independent apoptosis. Chromium 41-49 tumor protein p53 Homo sapiens 84-87 15163545-1 2004 It has been reported that the hexavalent chromium compound (Cr(VI)) can induce both p53-dependent and p53-independent apoptosis. Chromium 41-49 tumor protein p53 Homo sapiens 102-105 15163545-4 2004 When human lymphoma U937 cells, p53 mutated cells, were treated with 20 microM Cr(VI) for 24 h, nuclear morphological changes and DNA fragmentation were observed. Chromium 79-81 tumor protein p53 Homo sapiens 32-35 14971655-17 2004 These data suggest that both p53-dependent and -independent apoptotic and growth-inhibitory pathways are markedly affected by Cr(VI) exposure. Chromium 126-128 tumor protein p53 Homo sapiens 29-32 14971655-3 2004 Under certain conditions, some hexavalent chromium [Cr(VI)] compounds are toxic and carcinogenic in the human respiratory tract, and we have shown that they induce apoptosis and/or cell cycle arrest in a p53-dependent fashion. Chromium 42-50 tumor protein p53 Homo sapiens 204-207 12727806-4 2003 It has been reported that lung cancer from workers exposed to Cr(VI) has a high percentage of G to T transversion mutations in the non-transcribed strand of the p53 gene, a hallmark of PAH-induced mutation. Chromium 62-64 tumor protein p53 Homo sapiens 161-164 12727806-6 2003 These results raise the possibility that Cr(VI) may enhance PAH binding at the p53 gene in lung tissue. Chromium 41-43 tumor protein p53 Homo sapiens 79-82 12644821-8 2003 Another novel finding is that CR was negatively influenced by high BAX expression in all patients group (P=0.047) and by BCL2 expression in the TP53(-) group (P=0.05). Chromium 30-32 tumor protein p53 Homo sapiens 144-148 12060632-12 2002 The 64 DCC-positive patients with wild p53, N-ras, and FLT3 had statistically better CR attainment compared with the other 106 patients (P < 0.0001). Chromium 85-87 tumor protein p53 Homo sapiens 39-42 11323395-0 2001 Mechanisms of Cr(VI)-induced p53 activation: the role of phosphorylation, mdm2 and ERK. Chromium 14-16 tumor protein p53 Homo sapiens 29-32 11323395-4 2001 The degradation of p53 was dramatically decreased upon stimulation by Cr(VI). Chromium 70-72 tumor protein p53 Homo sapiens 19-22 10942736-13 2000 NADPH, which accelerated the one-electron reduction of Cr(VI) to Cr(V) and increased.OH radical generation, dramatically enhanced p53 activation. Chromium 55-57 tumor protein p53 Homo sapiens 130-133 10942736-13 2000 NADPH, which accelerated the one-electron reduction of Cr(VI) to Cr(V) and increased.OH radical generation, dramatically enhanced p53 activation. Chromium 65-67 tumor protein p53 Homo sapiens 130-133 10788560-7 2000 P53 levels increased 4- to 6-fold in chromium-treated cells. Chromium 37-45 tumor protein p53 Homo sapiens 0-3 10900468-8 2000 The necessity of p53 for chromium-induced apoptosis was examined in two ways. Chromium 25-33 tumor protein p53 Homo sapiens 17-20 10900468-10 2000 These studies showed that chromium-induced apoptosis was p53 dependent. Chromium 26-34 tumor protein p53 Homo sapiens 57-60 9769362-12 1998 Cr-induced DNA-DNA interstrand crosslinks (DDC), the tumor suppressor gene p53 and oxidative processes are some of the major factors that may play a significant role in determining the cellular outcome in response to Cr exposure. Chromium 217-219 tumor protein p53 Homo sapiens 75-78 10719810-7 2000 Multivariate analysis revealed that p53 positive group was associated with less CR rate compared to the p53 negative group (p=0.046), whereas overall survival was correlated with stage (p=0.0320), not with p53 status. Chromium 80-82 tumor protein p53 Homo sapiens 36-39 10719810-8 2000 p53 expression was associated with less CR rate in patients with DLBL. Chromium 40-42 tumor protein p53 Homo sapiens 0-3 10574974-6 1999 p53 is activated by Cr(VI), mostly by ROS-mediated free radical reactions. Chromium 20-22 tumor protein p53 Homo sapiens 0-3 10405637-5 1999 Complete remission (CR) was observed in 9 of the 17 patients (53%) with mutated forms of p53 and 18 of the 35 patients (51%) with wild-type p53 genes. Chromium 20-22 tumor protein p53 Homo sapiens 89-92 9098910-2 1997 The serum levels of pantropic p53 proteins were determined in workers with past exposure to hexavalent chromium compounds. Chromium 103-111 tumor protein p53 Homo sapiens 30-33 34570571-5 2021 In the patients with a stable disease, strong significant negative correlations between Cho/Cr and Cho/NAA with p53 mutation (-0.945 and -0.812 respectively, p < 0.05) and between Cho/Cr and IDH1, 2 mutation (-0.796, p < 0.05) were found. Chromium 92-94 tumor protein p53 Homo sapiens 112-115 8609696-10 1996 The CR rates overall and of primary tumors tended to be higher in the p53-positive than negative group, but the differences were not significant. Chromium 4-6 tumor protein p53 Homo sapiens 70-73 34570571-6 2021 In the patients with tumour progression, a significant positive correlation of NAA/Cr with 1p19q codeletion (0.486, p < 0.05) and of Cho/Cr and Cho/NAA values with p53 mutation (0.477 and 0.416, p < 0.05) were identified. Chromium 137-139 tumor protein p53 Homo sapiens 164-167